Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| GBI Research Guidance | 9 | 1 |
| Overview | 10 | 6 |
| Introduction to Drug/Device Combination Products | 10 | 1 |
| Commercialization Cycle of a Drug/Device CP | 11 | 1 |
| Categorization | 11 | 1 |
| The PMOA rule | 11 | 1 |
| A Request for Designation (RFD) | 11 | 1 |
| Device and Drug Classification | 12 | 1 |
| Clinical Investigation | 12 | 1 |
| Pre-Market Approval (PMA) | 13 | 1 |
| Product Approval for Marketing | 13 | 1 |
| Drug/Device CP: Applications | 14 | 1 |
| Drug/Device CP: Products | 14 | 1 |
| Research Scope | 15 | 1 |
| Drug/Device CP Market Characterization | 16 | 12 |
| Global Drug/Device CP Market | 16 | 1 |
| Historical Revenues | 16 | 1 |
| Market Forecasts | 17 | 1 |
| Key Market Trends | 18 | 1 |
| Large Volumes of Research &Development are Expected to Bring Forth Several New Product Launches | 18 | 1 |
| Cross-Disciplinary Alliances are Becoming Inevitable | 19 | 1 |
| Geographical Organic and Inorganic Expansion into APAC and Other Developing Nations is Bound to Spurt Growth | 19 | 1 |
| Technology Trends | 20 | 1 |
| Design and Development Technologies are Maturating | 20 | 1 |
| Large Numbers of New Product Developments are Undertaken to Stay in the Race | 20 | 1 |
| Shifting of Healthcare Provision Modes from Treatment in a Hospital Setting to Disease Prevention and Home Based Care | 20 | 1 |
| Changes in Design Concepts have Emerged from Alliances Between Drugs and Devices Industries | 20 | 1 |
| Market Drivers | 21 | 1 |
| Advances in Technology are Driving Growth of the Drug/Device CP Market | 21 | 1 |
| Rising Awareness among the Stakeholders Accelerates Market Growth | 21 | 1 |
| The Combination Products Promise to Avoid Systemic Effects and Toxicity and increases Efficacy of Therapy | 22 | 1 |
| Reviving of failed pharmaceutical products Lowers Development Time and Costs to Launch Newer CPs | 22 | 1 |
| Greater positive effects than the medical device operating alone | 22 | 1 |
| Regulatory processes are gaining clarity worldwide to invite bigger market participation | 23 | 1 |
| Rising Medical insurance coverage in increasing Clinical Adoption Rates | 23 | 1 |
| Broadening Range of Applications for Drug/Device CPs will increase Market Volumes Aggressively | 23 | 1 |
| A Competitive Pressure to Achieve Corporate Goals Lure Medical Device Companies into this Space | 23 | 1 |
| Market Restraints | 24 | 1 |
| Several Jurisdiction Issues Deter Market Growth Considerably | 24 | 1 |
| A Changing Regulatory Environment Creates Confusion and Lack of Clarity among Participants | 24 | 1 |
| Patient Compliance for these Products has Lowered Slightly, and is Affecting Adoption Rates | 24 | 1 |
| The relatively High Investment Costs in the Market Curtails Market Growth Considerably | 24 | 1 |
| Market Challenges | 25 | 1 |
| Cross-Industry Partnership Issues is a Major Challenge to Market Growth | 25 | 1 |
| Non-standard PMOA determination processes is a noteworthy lacunae in the regulatory processes | 26 | 1 |
| Several Major Business Risks Exist Within this Industry | 26 | 1 |
| Technology Issues Result in Large Development Timelines and Market Slow-down | 26 | 1 |
| Key Opportunity Areas | 27 | 1 |
| Addressing Legal and Regulatory Challenges Will Enlighten Dark Areas within The System And Enable Easy Transgression Through The Regulatory Cycles | 27 | 1 |
| Improving Finance Attracting Ability of Emerging Research-Oriented Bio-Tech Companies Will Aid in Promoting R&D | 27 | 1 |
| Expanding Product Portfolio Using Existing Knowledge Base Will Enable Easier Market Entry and Expansion | 27 | 1 |
| Increasing Product Accessibility to All Geographies With Unmet Demands Will Increase Sales Volumes For The Key Market Players | 27 | 1 |
| Drug/Device CP Market: Segment Analysis And Forecasts | 28 | 24 |
| Drug-Eluting Stents | 28 | 1 |
| Segment Overview | 28 | 1 |
| Foreground | 28 | 1 |
| DES design | 28 | 1 |
| Development of the DES Market | 28 | 1 |
| Pipeline DES products: | 29 | 1 |
| Market Forecasts | 29 | 1 |
| Market Drivers | 30 | 1 |
| Advantages over BMS | 30 | 1 |
| Next- generation DES | 30 | 1 |
| 2-G DES Have Transformed the Interventional Cardiology Market | 31 | 1 |
| Greater Prevalence of the High-Risk Group | 31 | 1 |
| Greater Medical Reimbursement for DES Applications | 31 | 1 |
| Market Restraints | 31 | 1 |
| Undesired implications of the DAPT therapy | 31 | 1 |
| Adverse Effects Post-Surgery Restrict Market Growth | 31 | 1 |
| Preventive Measures for Occurrence of Coronary Disorders | 31 | 1 |
| Cost Consideration among DES and BMS Stents | 31 | 1 |
| Stiff Competition from Advanced Technologies | 32 | 1 |
| Market Opportunities | 32 | 1 |
| New generation DES reducing risk of late in-stent thrombosis | 32 | 1 |
| Research and Development | 32 | 1 |
| Demonstrating efficient cost effectiveness | 32 | 1 |
| Antimicrobial Catheters | 33 | 1 |
| Segment Overview | 33 | 1 |
| Catheter-related Infection | 33 | 1 |
| Development of Anti-microbial Catheters | 33 | 1 |
| Market Forecasts | 34 | 1 |
| Market Drivers | 35 | 1 |
| Lowered Hospitalization Costs | 35 | 1 |
| Rising Awareness | 35 | 1 |
| Greater prevalence of cardiac disorders, UTI that require surgical procedures | 35 | 1 |
| Stricter Regulations Worldwide | 35 | 1 |
| Market Restraints | 35 | 1 |
| Price constraints | 35 | 1 |
| Co-morbidities | 35 | 1 |
| Controversial Development of Drug Resistance | 35 | 1 |
| Absence of a Good Antibiotic Pipeline | 36 | 1 |
| Poor Quality of Available Data | 36 | 1 |
| Market Opportunities | 36 | 1 |
| Increasing Awareness of Physicians and Surgeons | 36 | 1 |
| Resolving reimbursement issues | 36 | 1 |
| Antibiotic-Loaded Bone Cements | 37 | 1 |
| Segment Overview | 37 | 1 |
| Introduction | 37 | 1 |
| Development of ALBC | 37 | 1 |
| Performance characteristics of ALBCs | 37 | 1 |
| Clinical Applications | 38 | 1 |
| Market Forecasts | 39 | 1 |
| Market Drivers | 40 | 1 |
| Effective Infection Control because of Localized Treatment | 40 | 1 |
| Decreased Healthcare Cost Burden | 40 | 1 |
| Greater life-expectancy | 40 | 1 |
| Drawbacks of Handmade Antibiotic Coatings on Bone Cements | 40 | 1 |
| Technological Advancements | 40 | 1 |
| Market Restraints | 41 | 1 |
| Antibiotic and its Dosage as per Chosen Product | 41 | 1 |
| Decreased Bacterial Resistance | 41 | 1 |
| Costlier Treatment lowers Market Adoption Considerably | 41 | 1 |
| Decreased Mechanical Strength of the Cement | 41 | 1 |
| Drug Eluting Beads (DEB) | 42 | 1 |
| Segment Overview | 42 | 1 |
| The Drug-eluting beads (DEB) technology platform | 42 | 1 |
| DEB in the treatment of cancer: Embolization therapy | 42 | 1 |
| Drug-Eluting Beads breakthrough studies: | 42 | 1 |
| Market Forecasts | 43 | 1 |
| Market Drivers | 44 | 1 |
| Advantages over conventional TACE | 44 | 1 |
| High prevalence of HCC in Asia and CRC in China/Japan | 44 | 1 |
| Organic Expansion Plans | 44 | 1 |
| Clinical Trial completion | 44 | 1 |
| Increasing Medical Insurance Coverage | 44 | 1 |
| Market Restraints | 44 | 1 |
| Scarce skilled resources and expensive DEB cancer therapy: | 44 | 1 |
| Occurrence of PES (post-embolization syndrome) | 44 | 1 |
| Lengthy procedural volumes in to make therapeutic procedures available for clinical usage | 45 | 1 |
| Photodynamic Therapy | 45 | 1 |
| Segment Overview | 45 | 1 |
| Introduction to the PDT Process | 45 | 1 |
| The three mechanisms of damaging the tumor cells | 46 | 1 |
| Treatable cancers: | 47 | 1 |
| Research and Development | 47 | 1 |
| Photosensitizing Agents | 47 | 1 |
| The three main classes of Photosensitizing Agents used are: | 47 | 1 |
| Clinically approved Photosensitizers: | 48 | 1 |
| Light Delivery: | 48 | 1 |
| Pipeline PDT Products: | 49 | 1 |
| Market Forecasts | 49 | 1 |
| Market Drivers | 50 | 1 |
| Localized treatment increases efficacy of the therapy | 50 | 1 |
| Treatment using PDT is patient friendly, clinically and economically | 50 | 1 |
| Application of one drug for multiple therapies | 50 | 1 |
| Limited Side effects and Additional Benefits lure Patients and Increase Adoption Rates | 50 | 1 |
| Technological Advancements | 50 | 1 |
| Market Restraints | 51 | 1 |
| Competition from Traditional Treatments | 51 | 1 |
| Clinical Issues | 51 | 1 |
| Procedure Repetition | 51 | 1 |
| Limited Applications | 51 | 1 |
| Limited Market Potential | 51 | 1 |
| Market Opportunities | 51 | 1 |
| Drug/Device CP Market: Geographical Analysis and Forecasts | 52 | 4 |
| The US Market | 52 | 2 |
| The European Union (EU) Market | 54 | 1 |
| The Rest-of-World (ROW) Market | 54 | 2 |
| Drug/Device CP Market: Regulatory Issues | 56 | 15 |
| Introduction | 56 | 1 |
| Common Regulatory Issues | 57 | 1 |
| Compliance Issues | 57 | 1 |
| Pre-Clinical Testing Issues | 57 | 1 |
| Sterilization Issues | 58 | 1 |
| Safety and Efficacy Issues | 58 | 1 |
| Good Manufacturing Practices (GMP) Issues | 58 | 1 |
| Packaging Issues | 58 | 1 |
| CMC Issues | 59 | 1 |
| Stability Issues | 59 | 1 |
| Patent Analysis and IPR Issues | 60 | 1 |
| Post_Market Surveillance | 60 | 1 |
| Incident Reporting | 60 | 1 |
| Adverse Event Reporting | 61 | 1 |
| Risk Management Issues | 61 | 1 |
| Reimbursement Issues | 61 | 1 |
| The FDA and the Office of the Combination Products (OCP) | 62 | 2 |
| The European Medical Device Directive (MDD) | 64 | 1 |
| Mode of Action (MOA) | 64 | 3 |
| Japanese Regulatory Approach: The MHLW | 67 | 1 |
| Drugs | 67 | 1 |
| Medical devices | 67 | 1 |
| CP Jurisdiction | 67 | 1 |
| The Australian Therapeutic Goods Administration (TGA) and the Office of Devices, Blood and Tissues (ODBT) | 68 | 1 |
| TGA Framework | 68 | 1 |
| Key Challenges faced under the TGA by CP Manufacturers | 69 | 1 |
| State Food and Drug Administration (SFDA) and the Regulatory Framework in China | 69 | 1 |
| International Standards for Drugs and Devices | 70 | 1 |
| Drug/Device CP Market: Competitive Landscape | 71 | 17 |
| DES Market | 71 | 1 |
| Key Industry Participants | 71 | 1 |
| Key Company Profiles | 72 | 1 |
| Abbott Vascular | 72 | 1 |
| Medtronic, Inc. | 72 | 1 |
| Boston Scientific Corporation | 72 | 1 |
| Company Market Shares | 73 | 1 |
| Key Product Portfolios | 74 | 1 |
| Some other DES that have received clinical approval | 75 | 1 |
| DES in Development Stage | 75 | 1 |
| Antimicrobial Catheters | 76 | 1 |
| Key Industry Participants | 76 | 1 |
| Key Company Portfolios | 76 | 1 |
| Teleflex Medical (Arrow International) | 76 | 1 |
| Rochester Medical Corporation | 76 | 1 |
| Company Market Shares | 77 | 1 |
| Key Product Portfolios | 77 | 1 |
| Antimicrobial Catheter Concepts | 77 | 2 |
| Antibiotic Loaded Bone Cement | 79 | 1 |
| Key Industry Participants | 79 | 1 |
| Key Company Portfolios | 79 | 1 |
| DePuy Orthopaedics (Johnson and Johnson) | 79 | 1 |
| Biomet, Inc. | 79 | 1 |
| Zimmer Holdings, Inc. | 79 | 1 |
| Company Market Shares | 80 | 1 |
| Key Product Portfolios | 81 | 1 |
| Drug- Eluting Beads | 82 | 1 |
| Key Industry Participants | 82 | 1 |
| Key Company Portfolios | 82 | 1 |
| Biocompatibles International plc | 82 | 1 |
| BioSphere Medical, Inc. (Merit Medical Systems) | 82 | 1 |
| Sirtex Medical Europe GmbH | 83 | 1 |
| Company Market Shares | 83 | 1 |
| Key Product Portfolios | 84 | 1 |
| DC Bead | 84 | 1 |
| LC Bead | 84 | 1 |
| Bead Block | 84 | 1 |
| SIR-Spheres | 84 | 1 |
| Photodynamic Therapy | 85 | 1 |
| Key Industry Participants | 85 | 1 |
| Key Company Portfolios | 85 | 1 |
| DUSA Pharmaceuticals | 85 | 1 |
| QLT, Inc.: | 85 | 1 |
| Rofin Australia: | 85 | 1 |
| Company Market Shares | 86 | 1 |
| Key Product Portfolios | 86 | 1 |
| Visudyne | 86 | 1 |
| Omnilux | 86 | 1 |
| Levulan Kerastick | 87 | 1 |
| Drug/Device CP Market: Strategic Consolidation | 88 | 3 |
| Mergers &Acquisitions (M&A) | 88 | 1 |
| Licensing &Partnerships | 88 | 1 |
| Other notable alliances: | 89 | 1 |
| Existing Alliances: | 89 | 1 |
| Future Outlook | 90 | 1 |
| Appendix | 91 | 5 |
| Abbreviations | 91 | 2 |
| Definitions | 93 | 1 |